Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-05
DOI
10.1038/s41419-020-2505-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCL2 blockade overcomes MCL1 resistance in multiple myeloma
- (2019) Ka Tat Siu et al. LEUKEMIA
- Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
- (2019) Shannon M. Matulis et al. LEUKEMIA
- Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
- (2019) Esperanza M Algarín et al. HAEMATOLOGICA
- Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)
- (2019) Dawn Swan et al. HAEMATOLOGICA
- Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells
- (2018) Justine Debernardi et al. ONCOGENE
- Parallel derivation of isogenic human primed and naive induced pluripotent stem cells
- (2018) Stéphanie Kilens et al. Nature Communications
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia
- (2018) Haley E. Ramsey et al. Cancer Discovery
- Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
- (2018) Benoît Tessoulin et al. Journal of Hematology & Oncology
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
- (2016) J.-N. Gong et al. BLOOD
- Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia
- (2016) Patrick D. Bhola et al. JOURNAL OF CLINICAL INVESTIGATION
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines
- (2015) Sophie Maïga et al. CYTOMETRY PART A
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
- (2015) C Touzeau et al. LEUKEMIA
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
- (2015) Charlotte Kervoëlen et al. Oncotarget
- NbClust: AnRPackage for Determining the Relevant Number of Clusters in a Data Set
- (2015) Malika Charrad et al. Journal of Statistical Software
- Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function
- (2014) S B Ma et al. CELL DEATH AND DIFFERENTIATION
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- ABT-737 is highly effective against molecular subgroups of multiple myeloma
- (2011) L. Bodet et al. BLOOD
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria
- (2011) Fabien Llambi et al. MOLECULAR CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now